Lux 1, totally agree. Years ago, Rheoth ( ealier stage Poloxamer-188) was shown to have some pretty spectacular results ( IMHO) with heart attack. Currently, hematology studies using [Purified] Poloxamer-188, are displaying the potential benefits shared between Sickle Cell Disease treatment , cardiac failure and stroke treatments; the connection being that this drug is administered to the blood, impacting such blood and vascular surface factors as cellular aggregation, destruction, adhesion, viscosity, etc. Certain of these benefits would obviously overlap in varied diagnostic categories, due to the fact that blood and blood vessel health are common links to so many diseases and organ structures. Earlier this year MSTX joined forces with BSAF ( international chemical development/ production company) to produce an advanced purification on the Poloxamer - 188 product, for the cardiac failure studies. Ongoing provisionals and patenting of formulations ensures and protects the expanding MSTX product pipeline for future exclusivity. According to my understanding, the FDA determined that certain findings of prior SCD studies could be incorporated in the more current EPIC series/ studies, saving the time of replicating each study component. Fast track status says a lot about FDA's perception of the current needs in treatment of Sickle Cell Disease, IMO. ( EPIC trial 3 for SCD, using MST 188 , nearing completion). It will be very interesting to see how the FDA coordinates with the MSTX, phase 2 heart failure trial , concurrently running .
The mission here seems to be the sharing of accurate information from one investor to another. As I do not represent any specific entity, it is appreciated that correction be offered if my interpretations lack validity. All stated IMO.
